6qgh: Difference between revisions
From Proteopedia
Jump to navigationJump to search
m Protected "6qgh" [edit=sysop:move=sysop] |
No edit summary |
||
| Line 1: | Line 1: | ||
==Structure of human Bcl-2 in complex with ABT-263== | |||
<StructureSection load='6qgh' size='340' side='right'caption='[[6qgh]], [[Resolution|resolution]] 2.00Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[6qgh]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6QGH OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6QGH FirstGlance]. <br> | |||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=1XJ:4-(4-{[2-(4-CHLOROPHENYL)-5,5-DIMETHYLCYCLOHEX-1-EN-1-YL]METHYL}PIPERAZIN-1-YL)-N-[(4-{[(2R)-4-(MORPHOLIN-4-YL)-1-(PHENYLSULFANYL)BUTAN-2-YL]AMINO}-3-[(TRIFLUOROMETHYL)SULFONYL]PHENYL)SULFONYL]BENZAMIDE'>1XJ</scene></td></tr> | |||
[[Category: | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[6qg8|6qg8]], [[6qgg|6qgg]]</td></tr> | ||
[[Category: | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6qgh FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6qgh OCA], [http://pdbe.org/6qgh PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6qgh RCSB], [http://www.ebi.ac.uk/pdbsum/6qgh PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6qgh ProSAT]</span></td></tr> | ||
</table> | |||
== Disease == | |||
[[http://www.uniprot.org/uniprot/BCL2_HUMAN BCL2_HUMAN]] Note=A chromosomal aberration involving BCL2 has been found in chronic lymphatic leukemia. Translocation t(14;18)(q32;q21) with immunoglobulin gene regions. BCL2 mutations found in non-Hodgkin lymphomas carrying the chromosomal translocation could be attributed to the Ig somatic hypermutation mechanism resulting in nucleotide transitions. | |||
== Function == | |||
[[http://www.uniprot.org/uniprot/BCL2_HUMAN BCL2_HUMAN]] Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1).<ref>PMID:18570871</ref> | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Large Structures]] | |||
[[Category: Casara, P]] | |||
[[Category: Chen, I]] | [[Category: Chen, I]] | ||
[[Category: Davidson, J]] | [[Category: Davidson, J]] | ||
[[Category: Davis, B]] | [[Category: Davis, B]] | ||
[[Category: Diguarher, T Le]] | |||
[[Category: Dokurno, P]] | |||
[[Category: Geneste, O]] | |||
[[Category: Graham, C J]] | |||
[[Category: Harris, R]] | |||
[[Category: Hickman, J]] | [[Category: Hickman, J]] | ||
[[Category: Hubbard, R E]] | |||
[[Category: Jordan, A M]] | |||
[[Category: Kotschy, A]] | |||
[[Category: Matassova, N]] | |||
[[Category: Murray, J]] | |||
[[Category: Pedder, C]] | |||
[[Category: Ray, S]] | |||
[[Category: Roughley, S]] | |||
[[Category: Smith, J]] | |||
[[Category: Stark, J]] | [[Category: Stark, J]] | ||
[[Category: Walmsley, C]] | |||
[[Category: Wang, Y]] | |||
[[Category: Whitehead, N]] | [[Category: Whitehead, N]] | ||
[[Category: | [[Category: Williamson, D S]] | ||
[[Category: Abt-263]] | |||
[[Category: Apoptosis]] | |||
[[Category: | [[Category: Bcl2]] | ||
[[Category: | [[Category: Drug design]] | ||
[[Category: | |||
[[Category: | |||
Revision as of 05:46, 12 June 2019
Structure of human Bcl-2 in complex with ABT-263
| ||||||||||||
